Acumen Pharmaceuticals (ABOS) Short term Debt (2025 - 2026)

Acumen Pharmaceuticals has disclosed Short term Debt across 2 years of filings, most recently posting $19.7 million for Q2 2026.

• In Q2 2026, Short term Debt changed N/A year-over-year to $19.7 million; the TTM figure through Jun 2026 stood at $19.7 million (changed N/A YoY), while the FY2025 annual figure was $8.8 million, changed N/A from the prior year.
• Short term Debt came in at $19.7 million for Q2 2026 at Acumen Pharmaceuticals, up from $14.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $19.7 million in Q2 2026 to a low of $3.6 million in Q3 2025.